Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: A randomised, phase 3, double-blind, double-dummy, non-inferiority study

The Lancet Oncology

Volumn 17, Issue 3, 2016, Pages 332-344

  Kovács, Gábor ^a   Wachtel, Antonio E ^b   Basharova, Elena V ^c   Spinelli, Tulla ^d   Nicolas, Pierre ^d   Kabickova, Edita ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^c Chelyabinsk Pediatric Regional Clinical Hospital   (Russian Federation)

^d HELSINN HEALTHCARE SA   (Switzerland)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONDANSETRON; PALONOSETRON; ANTIEMETIC AGENT; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSKINESIA; EASTERN EUROPE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HUMAN; INFANT; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEWBORN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; RUSSIAN FEDERATION; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SKIN DISEASE; SOUTH AND CENTRAL AMERICA; THORAX DISEASE; TREATMENT RESPONSE; UNITED STATES; WESTERN EUROPE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW UP; INTERNATIONAL COOPERATION; MORTALITY; NAUSEA; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INTERNATIONALITY; ISOQUINOLINES; MALE; NAUSEA; NEOPLASMS; ONDANSETRON; QUINUCLIDINES; TREATMENT OUTCOME; VOMITING;

EID: 84960501843     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00520-3     Document Type: Article

References (37)

1. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996, 7:189-195.
2. Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer 2011, 19:S37-S42.
3. Laszlo J, Lucas VS Emesis as a critical problem in chemotherapy. N Engl J Med 1981, 305:948-949.
4. Basch E The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362:865-869.
5. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004, 100:2261-2268.
6. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J Quality of life studies in chemotherapy-induced emesis. Oncology 1996, 53:92-95.
7. Lin SJ, Hatoum HT, Buchner D, Cox D, Balu S Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study. BMC Health Serv Res 2012, 12:215.
8. Popovic M, Warr DG, Deangelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2014, 22:1685-1697.
9. Farrell C, Brearley SG, Pilling M, Molassiotis A The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. Support Care Cancer 2013, 21:59-66.
10. Jordan K, Sippel C, Schmoll HJ Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007, 12:1143-1150.
11. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21:v232-v243.
12. Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2013, 60:1073-1082.
13. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003, 98:2473-2482.
14. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003, 14:1570-1577.
15. Likun Z, Xiang J, Yi B, Xin D, Tao ZL A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 2011, 16:207-216.
16. Navari RM Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents. J Support Oncol 2003, 1:89-103.
17. Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010, 6:1073-1084.
18. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010, 335:362-368.
19. Rojas C, Slusher BS Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012, 684:1-7.
20. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008, 107:469-478.
21. Aapro M, Bourke JP Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer 2003, 39:927-931.
22. Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996, 28:53-59.
23. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994, 12:1045-1049.
24. Yu Z, Liu W, Wang L, et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 2009, 17:99-102.
25. Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur Rev Med Pharmacol Sci 2012, 16:462-468.
26. Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012, 20:1435-1439.
27. Yavas C, Dogan U, Yavas G, Araz M, Ata OY Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 2012, 20:2343-2347.
28. Miettinen O, Nurminen M Comparative analysis of two rates. Stat Med 1985, 4:213-226.
29. Wangge G, Putzeist M, Knol MJ, et al. Regulatory scientific advice on non-inferiority drug trials. PLoS One 2013, 8:e74818.
30. Kadota R, Shen S, Messinger Y Safety, pharmacokinetics and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study. Proc Am Soc Clin Oncol 2007, 25. (abstr) 9570.
31. Alvarez O, Freeman A, Bedros A, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995, 17:145-150.
32. Jaing TH, Tsay PK, Hung IJ, Yang CP, Hu WY Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2004, 21:227-235.
33. Sandoval C, Corbi D, Strobino B, Fevzi Ozkaynak M, Tugal O, Jayabose S Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 1999, 17:309-313.
34. Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 2008, 39:601-606.
35. Nadaraja S, Mamoudou AD, Thomassen H, Wehner PS, Rosthoej S, Schroeder H Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 2012, 59:870-873.
36. Birch JM, Blair V The epidemiology of infant cancers. Br J Cancer Suppl 1992, 18:S2-S4.
37. Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 2015, 16:385-394.